

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 May 2025 (30.05.2025)



(10) International Publication Number
WO 2025/109003 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 7/08 (2006.01)
A61K 47/54 (2017.01) G01N 33/68 (2006.01)
C07K 7/06 (2006.01)

(21) International Application Number:

PCT/EP2024/082992

(22) International Filing Date:

20 November 2024 (20.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2023/082549

21 November 2023 (21.11.2023) EP

(71) Applicant: **3B PHARMACEUTICALS GMBH**

[DE/DE]; Magnusstrasse 11, 12489 Berlin (DE).

(72) Inventors: **AL-OBAIDI, Naowras**; Hauptstraße 6L,

10317 Berlin (DE). **OSTERKAMP, Frank**; Konrad-Zuse-
Str. 16, 12489 Berlin (DE). **SCHNEIDER, Eberhard**;
Kunersdorfer Straße 14, 14552 Michendorf OT Wilden-
bruch (DE). **HÖHNE, Aileen**; Wassersportallee 19c,
12527 Berlin (DE). **ZBORALSKI, Dirk**; Gutzkowstr. 7,
10827 Berlin (DE). **WAHSNER-TESCHNER, Jessica**;
Provesthöhe 15, 45257 Essen (DE). **SMERLING, Chris-
tiane**; Kadettenweg 52, 12205 Berlin (DE). **REINEKE, Ul-
rich**; Rosensteinweg 25, 14193 Berlin (DE). **DRÄGER,
Carolin**; Am Weinberg 20, 15754 Heidesee OT Gussow
(DE). **NIKOLAEVA, Olga**; Fuldastr. 59, 12043 Berlin
(DE). **REIMER, Ulf**; Dunckerstr. 25, 10437 Berlin (DE).

(74) Agent: **HOFFMANN EITLE PATENT- UND**

RECHTSANWÄLTE PARTMBB, ASSOCIATION NO.
151; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: P-CADHERIN LIGANDS

(57) Abstract: The present invention is related to a P-cadherin binding compound; a composition comprising the P-cadherin binding compound; the P-cadherin binding compound and the composition, respectively, for use in a method for the diagnosis of a disease; the P-cadherin binding compound and the composition, respectively, for use in a method for the treatment of a disease; the P-cadherin binding compound and the composition, respectively, for use in a method of diagnosis and treatment of a disease which is also referred to as "thera(g)nosis" or "thera(g)nostics"; the P-cadherin binding compound and the composition, respectively, for use in a method for delivering a radionuclide to a P-cadherin expressing tissue; a method for the diagnosis of a disease using the P-cadherin binding compound and the composition, respectively; a method for the treatment of a disease using the P-cadherin binding compound and the composition, respectively; a method for the diagnosis and treatment of a disease which is also referred to as "thera(g)nosis" or "thera(g)nostics", using the P-cadherin binding compound and the composition, respectively; a method for the delivery of a radionuclide to a P-cadherin expressing tissue using the P-cadherin binding compound and the composition, respectively.

WO 2025/109003 A1